Domov › Rak želodca › Illinois

Klinične študije za Rak želodca v Illinois

19 študij za Rak želodca išče udeležence na lokacijah v Illinois.

Mesta v Illinois

Uradno besedilo študije (angleško)

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

OSF Saint Anthony's Health Center, Alton
Illinois CancerCare-Bloomington, Bloomington
Illinois CancerCare-Canton, Canton
in še 31

Vključevanje udeležencevVabljeni zdravi prostovoljci

Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07283939

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

OSF Saint Anthony's Health Center, Alton
Rush-Copley Medical Center, Aurora
Advocate Outpatient Center - Aurora, Aurora
in še 54

Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci

Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

University of Illinois Cancer Center, Chicago

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06172478

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Local Institution - 0379, Chicago

Vključevanje udeležencevFaza 2/3

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07221149

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Illinois Cancer Specialists, Arlington Heights
Illinois CancerCare - Bloomington, Bloomington
Illinois Cancer Specialists, Chicago
in še 7

Vključevanje udeležencevFaza 2/3

Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07392892

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

University of Illinois Cancer Center, Chicago
University of Chicago Medicine, Chicago
City of Hope - Chicago, Zion

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 10. sep. 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

University of Chicago, Chicago

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT06253871

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Research Site, Chicago
Research Site, Niles
Research Site, Zion

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07431281

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

University of Chicago, Chicago

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT04107077

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Orchard Healthcare Research Inc., Skokie

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 10. avg. 2026 · NCT06731478

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Ingalls Family Care Center, Calumet City
UChicago Medicine - River East, Chicago
The University Of Chicago, Chicago
in še 13

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 6. jul. 2026 · NCT04389632

Integrated Cancer Repository for Cancer Research

Rush-Copley Cancer Care Center, Aurora
Rush-Copley Healthcare Center, Yorkville

Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci

Starost 19–110 · Vsi spoli · Posodobljeno 29. jun. 2026 · NCT02012699

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
University of Chicago Medical Center /ID# 276271, Chicago

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 23. jun. 2026 · NCT05005403

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

University of Chicago Medical Center, Chicago

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 27. mar. 2026 · NCT06395519

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Northwestern University, Chicago
University of Chicago, Chicago

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 27. feb. 2026 · NCT06532006

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

University of Chicago, Chicago

Vključevanje udeležencevFaza 1/2

Starost 18–85 · Vsi spoli · Posodobljeno 29. jan. 2026 · NCT06055439

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Chicago

Vključevanje udeležencevOpazovalna študija

Vse starosti · Vsi spoli · Posodobljeno 28. okt. 2025 · NCT03452774

Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy

The University of Chicago, Chicago

Vključevanje udeležencevOpazovalna študija

Vse starosti · Vsi spoli · Posodobljeno 1. okt. 2025 · NCT01416714

A Study of NX-1607 in Adults With Advanced Malignancies

University of Chicago, Chicago

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2025 · NCT05107674

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.